View More Recent Stories

Feb 4, 2021 08:12AM Aldeyra Therapeutics (ALDX) Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Design
Feb 4, 2021 08:00AM Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Design
Jan 8, 2021 08:00AM Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect 2021 Virtual Conference
Jan 7, 2021 07:23AM Aldeyra Therapeutics (ALDX) Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease
Jan 7, 2021 07:00AM Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease
Jan 6, 2021 05:29PM Aldeyra Therapeutics (ALDX) to Host Conference Call and Webcast to Discuss Top-Line Symptom, Redness, and Schirmer’s Test Results from Run-in Cohort of Phase 3 TRANQUILITY Trial
Jan 6, 2021 04:30PM Aldeyra Therapeutics to Host Conference Call and Webcast to Discuss Top-Line Symptom, Redness, and Schirmer’s Test Results from Run-in Cohort of Phase 3 TRANQUILITY Trial
Dec 22, 2020 08:03AM Aldeyra Therapeutics (ALDX) Announces Confirmation of Antiviral Activity of ADX-1612
Dec 22, 2020 08:00AM Aldeyra Therapeutics Announces Confirmation of Antiviral Activity of ADX-1612
Dec 17, 2020 08:11AM Aldeyra Therapeutics (ALDX) Begins Phase 2 Clinical Trials of ADX-629 for Treatment of COVID-19
Dec 17, 2020 08:00AM Aldeyra Therapeutics Announces Initiation of Phase 2 Clinical Trials of ADX-629, a First-in-Class Orally Administered RASP Inhibitor, for the Treatment of COVID-19, Atopic Asthma, and Psoriasis
Dec 8, 2020 08:05AM Aldeyra Therapeutics (ALDX) Reports First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap
Dec 8, 2020 08:00AM Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Disease
Nov 13, 2020 08:00AM Aldeyra Therapeutics to Participate in the Jefferies and A.G.P./Alliance Global Partners Virtual Investor Conferences
Nov 5, 2020 07:00AM Aldeyra Therapeutics Announces Third-Quarter 2020 Financial Results and Provides Corporate Update
Nov 4, 2020 08:00AM Aldeyra to Participate in the American Academy of Ophthalmology Eyecelerator 2020 Virtual Conference on Friday, November 6
Oct 29, 2020 08:00AM Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2020 Financial Results and Corporate Update
Oct 22, 2020 08:00AM Aldeyra to Present New Reproxalap Data from Phase 2 Clinical Trial in Allergic Conjunctivitis at American Academy of Ophthalmology 2020 Annual Meeting
Sep 16, 2020 08:00AM Aldeyra to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Sep 10, 2020 08:00AM Aldeyra to Present at Cantor and H.C. Wainwright Virtual Investor Conferences
Sep 9, 2020 08:13AM Aldeyra Therapeutics (ALDX) Receives Study May Proceed Letter from FDA to Initiate Clinical Trial of ADX-629 in COVID-19 Patients
Sep 9, 2020 08:00AM Aldeyra Receives Study May Proceed Letter from FDA to Initiate Clinical Trial of ADX-629 in COVID-19 Patients
Sep 3, 2020 08:00AM Aldeyra to Participate in Citi’s 15th Annual BioPharma Virtual Conference
Aug 6, 2020 07:00AM Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update
Aug 4, 2020 08:00AM Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
Jul 30, 2020 08:00AM Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second-Quarter 2020 Financial Results and Corporate Update
Jul 14, 2020 08:06AM Aldeyra Therapeutics (ALDX) Announces Stock Sales to Perceptive Advisors and Avidity Partners
Jul 14, 2020 08:00AM Aldeyra Therapeutics Announces Stock Sales to Perceptive Advisors and Avidity Partners
Jul 13, 2020 04:05PM Aldeyra Therapeutics to Present at the OIS Virtual Public Company Showcase on July 16, 2020
Jul 7, 2020 08:07AM Aldeyra Therapeutics (ALDX) Announces NDA Development Plans for Dry Eye Disease
Jul 7, 2020 08:00AM Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease
Jun 15, 2020 08:03AM Aldeyra Therapeutics (ALDX) Receives Orphan Medicinal Product Designation from European Commission for ADX-2191 Retinal Disease Program
Jun 15, 2020 08:00AM Aldeyra Therapeutics Receives Orphan Medicinal Product Designation from the European Commission for ADX-2191 Retinal Disease Program
Jun 4, 2020 08:01AM Aldeyra Therapeutics (ALDX) Reports Agreement with FDA for Use of RASP as an Objective Sign for Treatment of Dry Eye Disease
Jun 4, 2020 08:00AM Aldeyra Therapeutics Reaches Agreement with the US Food and Drug Administration for the Use of RASP as an Objective Sign for the Treatment of Dry Eye Disease
Jun 3, 2020 08:00AM Aldeyra Therapeutics to Present at the Jefferies Virtual Healthcare Conference
May 20, 2020 07:01AM Aldeyra Therapeutics (ALDX) says ADX-1612 has demonstrated nanomolar potency against SARS-CoV-2 similar to or greater than that of remdesivir in an in vitro model
May 20, 2020 07:00AM Aldeyra Therapeutics to Advance ADX-1612, an Investigational New HSP90 Inhibitor with Potential Nanomolar Potency Against SARS-CoV-2, to Clinical Testing for COVID-19; ADX-629 Accepted for BARDA Coron
May 19, 2020 05:41PM Aldeyra Therapeutics (ALDX) to Host Conference Call and Webcast to Provide COVID-19 Development Update
May 19, 2020 04:05PM Aldeyra Therapeutics to Host Conference Call and Webcast to Provide COVID-19 Development Update
May 7, 2020 07:00AM Aldeyra Therapeutics Reports First-Quarter 2020 Financial Results and Announces New Clinical Programs
Oct 16, 2019 08:00AM ZAGENO Appoints Josef H. von Rickenbach as Chairman of its Board of Directors
Mar 19, 2019 08:30AM Stoke Therapeutics Appoints Industry Veteran Stephen Tulipano as Chief Financial Officer
Jun 26, 2015 10:00AM Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) to Ring The Nasdaq Stock Market Closing Bell
View More Recent Stories